Home » Stocks » DMPI

DelMar Pharmaceuticals, Inc. (DMPI)

Aug 20, 2020 - Stock symbol was changed to KTRA
Stock Price: $1.34 USD 0.00 (0.00%)
Updated Aug 19, 2020 4:00 PM EDT
Market Cap 15.35M
Revenue (ttm) n/a
Net Income (ttm) -7.90M
Shares Out 11.42M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Aug 19, 2020
Last Price $1.34
Previous Close $1.34
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.17 - 1.35
Day's Volume 0
52-Week Range 0.38 - 1.53


Hide News
PRNewsWire - 6 months ago

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.

PRNewsWire - 7 months ago

SAN DIEGO, July 17, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor canc...

Benzinga - 1 year ago

Shares of nano-cap biopharma DelMar Pharmaceuticals Inc (NASDAQ: DMPI) are trading sharply higher on over 40 times average volume.

Seeking Alpha - 1 year ago

DelMar Pharmaceuticals, Inc. (DMPI) CEO Saiid Zarrabian on Q3 2019 Results - Earnings Call Transcript

About DMPI

DelMar Pharmaceuticals, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. ... [Read more...]

Saiid Zarrabian
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements